Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EKF Diagnostics HoldingsLSE:EKF +1.60%45 EV-to-EBIT is 13.50 as of Aug. 28, 2026, which is 9% below its 10-year median of 14.76. GuruFocus rates LSE:EKF with a GF Score™ of 45/100 and a GF Value™ of £0.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 480 Medical Devices & Instruments companies, EKF Diagnostics Holdings ranks better than 65% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
EKF Diagnostics Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was £103.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EKF Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £7.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKF Diagnostics Holdings EV-to-EBIT Related Terms
EKF Diagnostics Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, EKF Diagnostics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EKF Diagnostics Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EKF Diagnostics Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where EKF Diagnostics Holdings's EV-to-EBIT falls into.
EKF Diagnostics Holdings's current Enterprise Value is £97.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EKF Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £7.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKF Diagnostics Holdings (LSE:EKF) has a EV-to-EBIT of 13.50 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EKF Diagnostics Holdings and its competitors. This is near median its historical median of 14.76. According to the industry distribution chart, EKF Diagnostics Holdings ranks #168 out of 480 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is EKF Diagnostics Holdings' EV-to-EBIT too high?
EKF Diagnostics Holdings' current EV-to-EBIT of 13.50 is near median its 10-year median of 14.76. The Medical Devices & Instruments industry median EV-to-EBIT is 18.86. EKF Diagnostics Holdings' value of 13.50 is 28.4% below this industry median. Based on the distribution chart, EKF Diagnostics Holdings ranks #168 out of 480 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, EKF Diagnostics Holdings has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EKF Diagnostics Holdings' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EKF Diagnostics Holdings ranks #168 out of 480 companies for EV-to-EBIT. This puts EKF Diagnostics Holdings in the upper half of its industry. The industry median EV-to-EBIT is 18.86. EKF Diagnostics Holdings' value of 13.50 is 28.4% below this benchmark. While the company's 10-year median is 14.76 vs. the industry median of 18.86, EKF Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.86, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EKF Diagnostics Holdings's current EV-to-EBIT of 13.50 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EKF Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EKF Diagnostics Holdings's current EV-to-EBIT is 13.50, which is near median its own 10-year median of 14.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EKF Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, EKF Diagnostics Holdings (LSE:EKF) is currently considered Fairly Valued. The stock's GF Value™ is £0.28, compared to a current price of £0.25 — trading 9.3% below its estimated fair value. The current EV-to-EBIT is 13.50, which is near median its 10-year median of 14.76 and 28.4% below the Medical Devices & Instruments industry median of 18.86. EKF Diagnostics Holdings' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For EKF Diagnostics Holdings (LSE:EKF), the current EV-to-EBIT is 13.50 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EKF Diagnostics Holdings (LSE:EKF) Overvalued in 2026?
Based on GuruFocus' analysis, EKF Diagnostics Holdings stock appears to be undervalued.
The current stock price of £0.25 is trading 9.3% below its estimated GF Value™ of £0.28.
GuruFocus considers EKF Diagnostics Holdings to be Fairly Valued.
Key valuation signals for LSE:EKF:
EV-to-EBIT: 13.50 (near median its 10-year median of 14.76)
GF Value™: £0.28 vs. price of £0.25 (9.3% below fair value)
Industry Position: 28.4% below the Medical Devices & Instruments median (#168 of 480)
No single metric tells the full story. See the LSE:EKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
45GF Score
Get the complete analysis for LSE:EKF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:EKF has been successfully added to your 
